Mayo Clinic: Myeloproliferative Disorders trials

The registry lists 10 Myeloproliferative Disorders studies with Mayo Clinic as lead sponsor. 1 are open to participants now and 5 have results posted.

Early Phase 1 1Phase 1 3Phase 2 6No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap NeoplasmsRecruitingNCT05549661Phase 1
• Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring SideroblastsTerminatedNCT05005182Phase 2Results posted
• WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT02666950Phase 2Results posted
• CC-4047 in Treating Patients With MyelofibrosisCompletedNCT00669578Phase 1/2Results posted
• Low-Dose Decitabine in Treating Patients With Symptomatic MyelofibrosisTerminatedNCT00630994Phase 2Results posted
• Azacitidine in Treating Patients With MyelofibrosisTerminatedNCT00381693Phase 2Results posted
• Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT StudyCompletedNCT05053100
• Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid MalignanciesCompletedNCT02129101Phase 1
• Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid MetaplasiaCompletedNCT00445900Phase 2
• Bortezomib in Treating Patients With Advanced Myeloproliferative DisordersCompletedNCT00437086Early Phase 1